viewPoolbeg Pharma PLC

Poolbeg Pharma raises £25mln ahead of AIM float

The company's lead product is a Phase II-ready treatment for flu

Open Orphan PLC -
Chief executive Jeremy Skillington has worked in the sector since 2002

Poolbeg Pharma PLC, a spin-out from Open Orphan PLC (LON:ORPH) is expected to float on AIM early next week after completing a £25mln fundraising.

The clinical-stage infectious diseases pharmaceutical company is being demerged from its parent company with aspirations to become a ‘one-stop shop’ for large pharma companies seeking mid-stage products to license or acquire.

Poolbeg, which boasts a capital-light and scalable business model where it aims to develop assets to be Phase II-ready quickly with modest investment, has issued its shares at 10p apiece and should have a market cap of £50mln when it arrives on London’s junior market on 19 July with a 51% free float.

Open Orphan confirmed today the £25mln funding had been successful.

Quick facts: Poolbeg Pharma PLC


Price: 10.75 GBX

Market Cap: £53.75 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


Poolbeg Pharma Presenting at the Proactive One2One Virtual Forum - 16th...

Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. Poolbeg aspires to become a “one-stop shop” for big pharma to...

1 week, 3 days ago

2 min read